A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice

CompletedOBSERVATIONAL
Enrollment

155

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

November 16, 2024

Study Completion Date

November 16, 2024

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Oral semaglutide

Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.

Trial Locations (1)

44425

Master Centre for Israel, Kfar Saba

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT05443568 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice | Biotech Hunter | Biotech Hunter